Rare diseases: The bane of modern society and the quest for cures

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 2, 2012, Pages 135-139

  Azie, N ^a   Vincent, J ^b  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ORPHAN DRUG; TRASTUZUMAB;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CANADA; CYSTIC FIBROSIS; FINLAND; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; HUMAN; INFECTION; MIDDLE EAST; PREVALENCE; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SOUTH AFRICA; UNITED STATES;

AGE FACTORS; DRUG DESIGN; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84864123779     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.97     Document Type: Review

References (17)

1. Yaneva-Deliverska, M. Rare diseases and genetic discrimination. J. IMAB-Annu. Proc. (Scientific Papers) 17, 116-119 (2011).
2. European Commission. Useful information on rare diseases from an EU perspective 〈http://ec.europa. eu/health/ph-information/documents/ ev20040705-rd05-en.pdf〉.
3. Rare Diseases Act of 2002 (Public Law 107-280) 〈http://history.nih. gov/research/downloads/PL107-280.pdf〉.
4. Duffy, A. Rare diseases' troubling questions. Cobourg Daily Star (Ontario), 25 January 2002.
5. Aronson, J.K. Editor's view. Rare diseases and orphan drugs. Br. J. Clin. Pharmacol. 61, 243-245 (2006). (Pubitemid 43382622)
6. Miklos, G.L.G. & Rubin, G.M. The role of the genome project in determining gene function: insights from model organisms. Cell 86, 521-529 (1996). (Pubitemid 26299484)
7. Clinuvel. Orphan drug designation (ODD) information 〈http://www. clinuvel.com/en/pharmaceuticaldevelopment/orphan-drug-designation〉.
8. Armstrong, W. Pharma's orphans. PharmExec. com 〈http://www. pharmexec.com/pharmexec/Strategy/Pharmas-Orphans/ArticleStandard/Article/detail/ 670568〉 (1 May 2010).
9. Woodcock, J. The future of orphan drug development. Clin. Pharmacol. Ther. 92, 146-148 (2012).
10. Kesselheim, A.S. Ethical considerations in orphan drug approval and use. Clin. Pharmacol. Ther. 92, 153-155 (2012).
11. Hudson, I. & Breckenridge, A. The challenges of orphan drugs and orphan diseases: real and imagined. Clin. Pharmacol. Ther. 92, 151-153 (2012).
12. Coles, L.D. & Cloyd, J.C. The role of academic institutions in the development of drugs for rare and neglected diseases. Clin. Pharmacol. Ther. 92, 193-202 (2012).
13. Lesko, L.J. Quantitative analysis to guide orphan drug development. Clin. Pharmacol. Ther. 92, 258-261 (2012).
14. Bashaw, E.D. et al. Clinical pharmacology as a cornerstone of orphan drug development. Nat. Rev. Drug Discov. 10, 795-796 (2011).
15. Orfali, M. et al. Raising orphans: how clinical development programs of drugs for rare and common diseases are different. Clin. Pharmacol. Ther. 92, 262-264 (2012).
16. Ian Phillips, M. Gene, stem cell, and future therapies for orphan diseases. Clin. Pharmacol. Ther. 92, 182-192 (2012).
17. Barry, M.A., Bezek, S., Serpa, J.A., Hotez, P.J. & Woc-Colburn, L. Neglected infections of poverty in Texas and the rest of the United States: management and treatment options. Clin. Pharmacol. Ther. 92, 170-181 (2012).